CytRx Corporation  

(Public, NASDAQ:CYTR)   Watch this stock  
3.29
+0.01 (0.30%)
Real-time:   12:48PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.25 - 3.37
52 week 2.08 - 5.46
Open 3.36
Vol / Avg. 340,900.00/691,596.00
Mkt cap 183.33M
P/E     -
Div/yield     -
EPS -0.54
Shares 55.72M
Beta 1.86
Inst. own 42%
Jun 24, 2015
CytRx Corp Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Apr 29, 2015
Q1 2015 CytRx Corp Earnings Release (Estimated) Add to calendar
Mar 10, 2015
Q4 2014 CytRx Corp Earnings Release
Mar 4, 2015
CytRx Corp at Cowen Health Care Conference
Feb 9, 2015
CytRx Corporation at Biotechnology Industry Organization CEO & Investor Conference
Jan 22, 2015
CytRx Corp Conference Call to Discuss Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in Soft Tissue Sarcoma - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -13437.78% -30117.98%
Operating margin -13097.88% -49605.86%
EBITD margin - -49422.93%
Return on average assets -59.07% -47.36%
Return on average equity -73.78% -76.66%
Employees 26 -
CDP Score - -

Address

Suite 650, 11726 San Vicente Blvd
LOS ANGELES, CA 90049
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is currently focused on the clinical development of aldoxorubicin, modified version of a chemotherapeutic agent, doxorubicin, and recently reported results of Phase 2b clinical trial with aldoxorubicin. Aldoxorubicin, formlerly INNO-206 is a tumor-targeted doxorubicin conjugate. Aldoxorubicin has been granted orphan drug designation by the Office of Orphan Product Development of the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer. CytRx has initiated a Phase III pivotal trial. The Company�s key products are: Aldoxorubicin, Bafetinib and Tamibarotene.

Officers and directors

Marvin R. Selter Independent Vice Chairman of the Board
Age: 86
Bio & Compensation  - Reuters
John Y. Caloz Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Daniel Levitt M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Benjamin S. Levin Senior Vice President, General Counsel, Corporate Secretary
Age: 38
Bio & Compensation  - Reuters
Douglas Scott Wieland Ph.D. Senior Vice President - Drug Development
Age: 55
Bio & Compensation  - Reuters
David J. Haen Vice President - Business Development
Age: 36
Bio & Compensation  - Reuters
Steven A. Kriegsman Chairman of the Board, President, Chief Executive Officer
Age: 73
Bio & Compensation  - Reuters
Anita J Chawla Director
Age: 56
Bio & Compensation  - Reuters
Louis J. Ignarro Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Joseph Rubinfeld Ph.D. Independent Director
Age: 82
Bio & Compensation  - Reuters